



# TITAN BIOTECH LTD.

AN ISO 9001:2008 CERTIFIED COMPANY



Corp.Off. : 303-305 Lusa Tower, Azadpur Comm. Complex, Delhi-33, India

Ph.: 011-47020100, 27677960, 27675668, 27674615 | Fax: +91-11-47619811 | CIN: L74999RJ1992PLC013387

Dated 29.10.2015

To,

Corporate Services Department  
BOMBAY STOCK EXCHANGE LIMITED  
PHIROZE JEEJEEBHOY TOWERS  
DALAL STREET  
MUMBAI- 400001

**Subject: Submission of Unaudited Financial Results.**

Dear Sir,

Enclosed also find the Unaudited Financial Results of the Company for the quarter ended 30<sup>th</sup> September, 2015. This is being filed pursuant to Clause 41 of the Listing Agreement signed between the Company and Bombay Stock Exchange Limited. The above have been approved by the Board of Directors in its meeting held today i.e., 29<sup>th</sup> October, 2015.

Thanking You

For Titan Biotech Limited

*Charanjit Singh*  
Authorised Signatory

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

Website: [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan  
 Phone No. 011-47020100, Fax No. +91-11-47619811 CIN : L74999RJ1992PLC013387  
 Email : hrd@titanbiotechltd.com Website : www.titanbiotechltd.com  
 UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEP., 2015

(Rs. IN LAKHS)

PARTICULARS	QUARTER ENDED			SIX MONTH ENDED		YEAR ENDED
	30.06.2015 Unaudited	30.09.2015 Unaudited	30.09.2014 Unaudited	30.09.2015 Unaudited	30.09.2014 Unaudited	31.03.2015 Audited
<b>PART I</b>						
1 INCOME FROM OPERATION						
a) Net Sales / Income from Operation	933.24	1233.70	1117.62	2166.94	2004.95	4031.61
b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total Income from Operation (Net)</b>	<b>933.24</b>	<b>1233.70</b>	<b>1117.62</b>	<b>2166.94</b>	<b>2004.95</b>	<b>4031.61</b>
2 EXPENDITURE						
(a) Cost of Materials Consumed	591.81	753.81	737.26	1345.62	1337.43	2653.00
(b) Changes in inventories of finished goods, work in progress and stock in trade	-7.14	30.42	4.40	23.28	-29.47	-129.26
(c) Employees benefit Expenses	68.93	88.16	68.82	157.09	132.40	273.06
(d) Depreciation & Amortisation Expenses	21.84	16.10	17.52	37.94	36.09	83.85
(e) Other Expenditure	188.04	247.79	200.17	435.83	368.77	846.56
<b>Total Expenditure</b>	<b>863.48</b>	<b>1136.28</b>	<b>1028.17</b>	<b>1999.76</b>	<b>1845.22</b>	<b>3727.21</b>
3 Profit from Operation before Other Income, finance costs & Exceptional Items	69.76	97.42	89.45	167.18	159.73	304.40
4 Other Income	7.33	10.28	4.14	17.61	11.30	39.84
5 Profit from ordinary activities before Finance Costs & Exceptional Items	77.09	107.70	93.59	184.79	171.03	344.24
6 Interest	19.06	38.26	26.37	57.32	48.06	99.23
7 Profit from Ordinary activities after Finance Costs but before Exceptional Items	58.03	69.44	67.22	127.47	122.97	245.01
8 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
<b>9 Profit(+)/Loss(-) before Tax (-)</b>	<b>58.03</b>	<b>69.44</b>	<b>67.22</b>	<b>127.47</b>	<b>122.97</b>	<b>245.01</b>
10 Tax Expenses						
(a) Provision for Taxation	19.72	23.60	22.85	43.33	41.80	71.98
(b) Provision for Deferred Tax	0.00	4.12	0.00	4.12	0.00	9.84
<b>Total Tax Expenses</b>	<b>19.72</b>	<b>27.72</b>	<b>22.85</b>	<b>47.45</b>	<b>41.80</b>	<b>81.82</b>
<b>11 Net Profit (+)/Loss(-) from Ordinary Activities after tax</b>	<b>38.31</b>	<b>41.72</b>	<b>44.37</b>	<b>80.02</b>	<b>81.17</b>	<b>163.19</b>
12 Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
13 Net Profit / Loss	38.31	41.72	44.37	80.02	81.17	163.19
14 Operating Profit Before Exceptional Items						
15 Paid-up Equity Share Capital	773.87	773.87	703.87	773.87	703.87	773.87
16 Reserve excluding Revaluation Reserve ( as per Balance Sheet)	N.A.	N.A.	N.A.	N.A.	N.A.	1273.47
17(I) Earning Per Share (before extraordinary items) Basic & Diluted	0.49	0.54	0.63	1.03	1.15	2.11
17(II) Earning Per Share ( after extraordinary items) Basic & Diluted	0.49	0.54	0.63	1.03	1.15	2.11
Annualised Basic EPS Before Extraordinary /exceptional items						
<b>A PARTICULARS OF SHAREHOLDING</b>						
1 Public Shareholding						
- Number of Shares	3974201	3974201	3623701	3974201	3623701	3974701
- Percentage of Shareholding	51.35	51.35	51.48	51.35	51.48	51.35
2 Promoters and promoter group shareholding						
A) Pledged/Encumbered						
-Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
-Percentage of shares (as a % of the total shareholding of promoter & promoter group)	0.00	0.00	0.00	0.00	0.00	0.00
-Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00
B) Non-encumbered						
-Number of shares	3764499	3764499	3414999	3764499	3414999	3763999
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	48.65	48.65	48.52	48.65	48.52	48.64
-Percentage of shares ( as a % of the total share capital of the company)	100.00	100.00	100	100.00	100	100
<b>B INVESTOR COMPLAINTS</b>						
	Quarter Ended 30.09.2015					
Pending at the beginning of the quarter	NIL					
Received during the quarter	2					
Disposed off during the quarter	2					
Remaining unresolved at the end of the quarter	NIL					



For Titan Biotech Limited  
*[Signature]*  
 Managing Director

The Statement of Assets and Liabilities as per Clause 41 of the Listing Agreement is as under:-

(Rs. In Lakhs)

PARTICULARS	AS AT	AS AT
	30.09.2015 (Unaudited)	31.03.2015 (Audited)
<b>A EQUITY AND LIABILITIES</b>		
1. Shareholders fund		
(a) Share Capital	773.870	773.870
(b) Reserve and Surplus	1353.480	1273.468
<b>Sub total- Shareholders' Fund</b>	<b>2127.350</b>	<b>2047.338</b>
2. Non-current Liabilities		
(a) Long Term borrowings	227.910	219.491
(b) Deferred Tax Liabilities(net)	40.450	36.327
(c) Other Long Term Liabilities	0.000	0.000
(d) Long Term Provisions	0.000	0.000
<b>Sub total- Non Current Liabilities</b>	<b>268.360</b>	<b>255.818</b>
3. Current Liabilities		
(a) Short Term borrowings	379.930	551.590
(b) Trade Payables	301.100	141.852
(c) Other Current Liabilities	198.080	212.162
(d) Short Term Provisions	43.330	141.832
<b>Sub total - Current Liabilities</b>	<b>922.440</b>	<b>1047.436</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>3318.150</b>	<b>3350.592</b>
<b>B ASSETS</b>		
1. Non Current Assets		
(a) Fixed Assets	1050.500	1082.909
(b) Cap. Work in progress	301.610	114.172
(c) Non Current Investments	4.990	4.994
(d) Long term Loans and Advance	43.900	22.585
(e) Other non-current assets	0.000	0.000
<b>Sub total Non-Current Assets</b>	<b>1401.000</b>	<b>1224.660</b>
2. Current Assets		
(a) Inventories	848.140	1106.857
(b) Trade Receivables	574.650	641.335
(c) Cash and cash equivalents	256.550	36.008
(d) Short-Term Loan and Advances	109.000	137.494
(e) Other Current Assets	128.810	204.238
<b>Sub total - Current Assets</b>	<b>1917.150</b>	<b>2125.932</b>
<b>TOTAL ASSETS</b>	<b>3318.150</b>	<b>3350.592</b>

Notes:

1. The above statement of financial results was taken on record by the Board of Directors at their meeting held on 29th Oct. 2015.
2. A Limited review of the financial results of the quarter ended 30th Sep. 2015 has been carried out by the Statutory Auditors of the company pursuant to Clause 41 of the Listing Agreement.
3. Previous period figures are regrouped/reclassified in line with the current period.

For and behalf of Board of Directors  
for TITAN BIOTECH LTD.

*Naresh Kumar Singh*  
Naresh Kumar Singh  
Managing Director

Place : New Delhi  
Dated : 29.10.2015

